HYDROCORTISONE PANPHARMA 100 MG

Kraj: Izrael

Język: angielski

Źródło: Ministry of Health

Składnik aktywny:

HYDROCORTISONE AS SODIUM SUCCINATE

Dostępny od:

PHARMALOGIC LTD

Forma farmaceutyczna:

POWDER FOR SOLUTION FOR INJECTION

Skład:

HYDROCORTISONE AS SODIUM SUCCINATE 100 MG/DOSE

Droga podania:

I.M, I.V

Typ recepty:

Required

Wyprodukowano przez:

PANPHARMA, FRANCE

Wskazania:

Hydrocortisone panpharma is indicated to treat any condition in which IM or IV corticosteroid treatment is required such as: - allergic states, - dermatologic diseases, - endocrine disorders, - gastrointestinal diseases,- hematologic disorders, - neoplastic diseases, - nervous system disorders, - ophthalmic diseases, - renal diseases, - respiratory diseases, - rheumatic disorders,- certain medical emergencies.

Data autoryzacji:

2014-07-31

Charakterystyka produktu

Literature reports suggest an apparent association between use of
corticosteroids and left ventricular free wall rupture after a recent
myocardial infarction; therefore, therapy with corticosteroids
should be used with great caution in these patients.
_ENDOCRINE:_
Hypothalamic-pituitary adrenal (HPA) axis suppression. Cushing’s
syndrome, and hyperglycemia. Monitor patients for these
conditions with chronic use. Corticosteroids can produce reversible
HPA axis suppression with the potential for glucocorticosteroid
insufficiency after withdrawal of treatment. Drug-induced
secondary adrenocortical insufficiency may be minimized by
gradual reduction of dosage. This type of relative insufficiency
may persist for months after discontinuation of therapy; therefore,
in any situation of stress occurring during that period, hormone
therapy should be reinstituted.
_INFECTIONS GENERAL:_
Patients who are on corticosteroids are more susceptible to
infections than are healthy individuals. There may be decreased
resistance and inability to localize infection when corticosteroids
are used. Infection with any pathogen (viral, bacterial, fungal,
protozoan or helminthic) in any location of the body may be
associated with the use of corticosteroids alone or in combination
with other immunosuppressive agents.
These infections may be mild, but can be severe and at times fatal.
With increasing doses of corticosteroids, the rate of occurrence
of infectious complications increases. Corticosteroids may also
mask some signs of current infection. Do not use intra-articularly,
intrabursally or for intratendinous administration for _local_ effect
in the presence of acute local infection.
_FUNGAL INFECTIONS:_
Corticosteroids may exacerbate systemic fungal infections and
therefore should not be used in the presence of such infections
unless they are needed to control drug reactions. There have
been cases reported in which concomitant use of amphotericin
B and hydrocortisone was followed by cardiac enlargement
and congestive heart failure (see C